Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 10/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745053 | 0.86 | SLC6A4 (0.53) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL925035 | 0.86 | SLC6A4 (0.46) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22262492 | 0.83 | SLC6A4 (0.46) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3713282 | 0.83 | SLC6A4 (0.43) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3713287 | 0.83 | SLC6A4 (0.43) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20745095 | 0.83 | SLC6A4 (0.43) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3713288 | 0.83 | SLC6A4 (0.43) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1346422 | 0.82 | SLC6A4 (0.58) | SLC6A4L3MBTL1MAPTALDH1A1HTR1A | |
| SCHEMBL3713284 | 0.82 | SLC6A4 (0.42) | SLC6A4L3MBTL1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30808273 | 0.81 | SLC6A4 (0.57) | SLC6A4L3MBTL1SMN1; SMN2ALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SLC6A4 4507/4885L3MBTL1 76/4885MAPT 4497/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SLC6A4 4507/4885L3MBTL1 76/4885MAPT 4497/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SLC6A4 4507/4885L3MBTL1 76/4885MAPT 4497/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SLC6A4 4507/4885L3MBTL1 76/4885MAPT 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.